Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alissa Visram

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Leukemia|July 2, 2024
Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, et al.
Leukemia|February 22, 2022
Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, et al.
American Journal of Hematology|June 19, 2023
A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)Alissa Visram, Suzanne R Hayman, Angela Dispenzieri, et al.
Blood Cancer Journal|November 27, 2021
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosisAlissa Visram, S Vincent Rajkumar, Prashant Kapoor, et al.
Ejhaem|December 5, 2022
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) DatabaseArleigh McCurdy, Martha Louzada, Christopher P Venner, et al.
European Journal of Haematology|August 13, 2023
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysisRichard LeBlanc, Hira Mian, Donna Reece, et al.
Blood Cancer Journal|December 6, 2022
Second- and third-line treatment strategies in multiple myeloma: a referral-center experienceSarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 14, 2025
Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in CanadaHira S Mian, Alissa Visram, Steven Chun-Min Shih, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2023
Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple MyelomaSarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, et al.
Blood Cancer Journal|August 27, 2023
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysisArleigh McCurdy, Hira Mian, Richard LeBlanc, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Leukemia|July 2, 2024
Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, et al.
Leukemia|February 22, 2022
Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, et al.
American Journal of Hematology|June 19, 2023
A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)Alissa Visram, Suzanne R Hayman, Angela Dispenzieri, et al.
Blood Cancer Journal|November 27, 2021
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosisAlissa Visram, S Vincent Rajkumar, Prashant Kapoor, et al.
Ejhaem|December 5, 2022
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) DatabaseArleigh McCurdy, Martha Louzada, Christopher P Venner, et al.
European Journal of Haematology|August 13, 2023
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysisRichard LeBlanc, Hira Mian, Donna Reece, et al.
Blood Cancer Journal|December 6, 2022
Second- and third-line treatment strategies in multiple myeloma: a referral-center experienceSarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 14, 2025
Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in CanadaHira S Mian, Alissa Visram, Steven Chun-Min Shih, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2023
Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple MyelomaSarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, et al.
Blood Cancer Journal|August 27, 2023
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysisArleigh McCurdy, Hira Mian, Richard LeBlanc, et al.
Pageof 8